Graphite Bio (NASDAQ:GRPH) Trading 0.4% Higher

Graphite Bio, Inc. (NASDAQ:GRPH) traded up 0.4% during trading on Friday . The company traded as high as $2.35 and last traded at $2.34. 63,669 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 179,417 shares. The stock had previously closed at $2.33.

Graphite Bio Trading Up 0.4 %

The stock has a 50 day simple moving average of $2.37 and a 200-day simple moving average of $2.61. The firm has a market cap of $135.67 million, a P/E ratio of -1.02 and a beta of -0.05.

Graphite Bio (NASDAQ:GRPH) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). As a group, equities analysts forecast that Graphite Bio, Inc. will post -1.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Graphite Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Privium Fund Management B.V. acquired a new position in shares of Graphite Bio in the second quarter valued at about $694,000. K2 Principal Fund L.P. increased its holdings in shares of Graphite Bio by 3,311.3% in the first quarter. K2 Principal Fund L.P. now owns 969,620 shares of the company’s stock valued at $2,376,000 after purchasing an additional 941,196 shares during the period. Barclays PLC increased its holdings in shares of Graphite Bio by 504.0% in the third quarter. Barclays PLC now owns 34,037 shares of the company’s stock valued at $85,000 after purchasing an additional 28,402 shares during the period. Landscape Capital Management L.L.C. acquired a new position in shares of Graphite Bio in the third quarter valued at about $45,000. Finally, SG Americas Securities LLC acquired a new position in shares of Graphite Bio in the third quarter valued at about $31,000. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

Graphite Bio Company Profile

Graphite Bio, Inc, a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.